LENZ THERAPEUTICS, INC. Accrued Liabilities, Current
LENZ THERAPEUTICS, INC. (LENZ) had Accrued Liabilities, Current of $9.78 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Accrued Liabilities, Current $9.78M.
- 2026-03-31: Accrued Liabilities, Current $14.88M.
- 2025-12-31: Accrued Liabilities, Current $17.02M.
- 2025-09-30: Accrued Liabilities, Current $11.99M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $9.78M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $14.88M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $17.02M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $11.99M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $7.54M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $4.91M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $6.15M 10-K · filed 2026-03-24 |
| 2024-09-30 | $4.95M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $4.18M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $11.76M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $12.80M 10-K · filed 2025-03-19 |
| 2022-03-31 | $500.00K 10-Q · filed 2022-05-12 |
| 2021-09-30 | $300.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $45.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |